Biopharma's High Performers 2014

Accenture has launched the latest version of its annual study of the biopharmaceutical industry. The High Performance Business (HPB) report analyses  the long-term performance of the 16 largest pharma companies globally, highlighting industry trends, pharmaceutical business performance analysis, and potential implications for the industry.

Some highlights from this year’s study include:

• R&D pipeline is output up - pharma has entered a period of markedly improved R&D output - but the productivity crisis not fixed.

• In the last two years, FDA New Molecular Entity (NME) approvals are up approximately 30% on the last decade; they are expected to remain elevated over the next 5 years.

• In the emerging markets recent and upcoming launches are forecast to drive up to $140 billion in growth over the next 5 years. Strong growth from new products and emerging markets will help to overcome the $103 billion in revenue expected to be lost from patent expired drugs, making a positive overall trajectory for growth for the industry.

• New product launches are entering an unprecedentedly tough payer climate in developed markets.

• High Performers are more successfully bringing new science to market through launch capabilities that demonstrate whole system patient outcomes.

• High Performers display five key attributes that set them apart from their competitors:
  - They continue to harness collaborative R&D models.
  - They are committed to applying science to product launches focused on outcomes for specific patient groups.
  - They use flexible pricing strategies to meet patient population.
  - They display a mastery of multichannel marketing and patient services to reinforce patient outcomes.
  - They are fine tuning local operations to succeed in emerging markets.

For more information, visit the Accenture website.